Literature DB >> 34532137

Underlying mechanism of sorafenib resistance in hepatocellular carcinoma: a bioinformatics study based on validated resistance-related genes.

Yu Song1, Peng Gao2, Haiying Ding1, Gaoqi Xu1, Yan Hu1, Yinghui Tong1, Wenxiu Xin1, Liwen Zhang2, Miaolian Wu2,3, Luo Fang1.   

Abstract

BACKGROUND: Sorafenib, the first approved targeted therapy for advanced hepatocellular carcinoma (HCC), is often reported to comprised survival-benefit due to resistance. An underlying mechanism of resistance was proposed using bioinformatics analysis based on differentially expressed genes (DEGs) from microarrays. However, most DEGs were invalidated at both the expression level, and the role in causing resistance. Therefore, we conducted a bioinformatics analysis based on experimentally determined sorafenib-resistance-related genes (SRRGs) to elucidate the mechanism of sorafenib resistance.
METHODS: The SRRGs, which have been experimentally determined to promote or inhibit resistance, were collected from published studies. The Database for Annotation, Visualization and Integrated Discovery (DAVID) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to perform Gene Ontology (GO) and pathway enrichment analysis, respectively. A corresponding protein-protein interaction network (PPI) was created using the Cytoscape software program, and network hub genes were proposed.
RESULTS: A total of 145 SRRGs, with 117 promoting and 28 inhibiting resistance, were identified. Cell proliferation, migration, development, response to oxygen levels, epithelial-to-mesenchymal transition (EMT), cell skeleton, protein function, and autophagy were all proposed as crucial gene functions related to resistance. The pathways related to cell proliferation or apoptosis, immune function, endocrine metabolism, stem cell function, and differentiation were identified as key resistance-related pathways. A total of 81 hub genes were proposed, including the following top 10 genes: TP53, AKT1, EGFR, STAT3, VEGFA, JUN, MAPK1, IL6, PTEN, and CTNNB1.
CONCLUSIONS: In conclusion, this study gathered experimentally validated genes that determine sorafenib resistance in HCC, provided an overview of the underlying mechanisms of resistance, and further validated sorafenib resistance in HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Sorafenib; bioinformatics analysis; hepatocellular carcinoma (HCC); resistance; validated resistance-related genes

Year:  2021        PMID: 34532137      PMCID: PMC8421901          DOI: 10.21037/jgo-21-377

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  35 in total

Review 1.  How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.

Authors:  Thorsten Stiewe; Tali E Haran
Journal:  Drug Resist Updat       Date:  2018-05-09       Impact factor: 18.500

2.  Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study.

Authors:  Jinli Lv; Bo Zhu; Liang Zhang; Qichao Xie; Wenlei Zhuo
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.

Authors:  Shao-Lai Zhou; Zheng-Jun Zhou; Zhi-Qiang Hu; Xiao-Wu Huang; Zheng Wang; Er-Bao Chen; Jia Fan; Ya Cao; Zhi Dai; Jian Zhou
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

4.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

5.  Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR.

Authors:  Jeanine S Morey; James C Ryan; Frances M Van Dolah
Journal:  Biol Proced Online       Date:  2006-12-12       Impact factor: 3.244

6.  Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.

Authors:  Zhen Qu; Junhua Wu; Junyi Wu; Dongjun Luo; Chunping Jiang; Yitao Ding
Journal:  J Exp Clin Cancer Res       Date:  2016-09-30

7.  A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies.

Authors:  Feifei Wang; Ruliang Wang; Qiuwen Li; Xueling Qu; Yixin Hao; Jingwen Yang; Huixia Zhao; Qian Wang; Guanghui Li; Fengyun Zhang; He Zhang; Xuan Zhou; Xioumei Peng; Yang Bian; Wenhua Xiao
Journal:  Diagn Pathol       Date:  2017-01-13       Impact factor: 2.644

8.  Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.

Authors:  Peng Han; Hali Li; Xian Jiang; Bo Zhai; Gang Tan; Dali Zhao; Haiquan Qiao; Bing Liu; Hongchi Jiang; Xueying Sun
Journal:  Mol Oncol       Date:  2017-02-17       Impact factor: 6.603

Review 9.  Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.

Authors:  Carolina Méndez-Blanco; Flavia Fondevila; Andrés García-Palomo; Javier González-Gallego; José L Mauriz
Journal:  Exp Mol Med       Date:  2018-10-12       Impact factor: 8.718

Review 10.  The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Annu Rev Biochem       Date:  2016-05-04       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.